Page last updated: 2024-10-31

midodrine and Prostatic Neoplasms

midodrine has been researched along with Prostatic Neoplasms in 1 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Prostatic Neoplasms: Tumors or cancer of the PROSTATE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shim, M1
Kim, J1
Park, S1
Choi, SK1
Lee, SM1
Huh, KO1
Song, C1
Choo, MS1
Ahn, H1

Trials

1 trial available for midodrine and Prostatic Neoplasms

ArticleYear
The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study.
    Urology, 2015, Volume: 85, Issue:5

    Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Midodrine; Musc

2015